Embody, Inc., a privately-held medical device company focused on soft tissue repair, closed a $9.3 million Series A funding round led by Litigit LLC, with participation from Cultivate (MD) and 757 Angels. The financing will enable Embody to expand its world-class team and the commercial launch Tapestry, its next-generation soft-tissue repair technology in the second half of 2020.
“This financing represents a significant step in the growth of Embody,” said Jeff Conroy, Embody’s co-founder and chief executive officer. “We are now in a position to execute on our goals of commercializing Tapestry, our first in a series of soft-tissue repair products for Achilles, rotator cuff and knee ligament injuries.”
Embody noted that the global market for sports medicine products is expected to reach $9 billion by 2024. Embody’s products focus on the repair of serious tendon and ligament injuries and are developed in close collaboration with advanced clinical thought leaders.
Founded in 2014 and funded with $20 million in DARPA & DOD funding, Embody is developing biomaterials with an initial focus on orthopedic applications including Achilles, rotator cuff and knee ligament repair.
Photo courtesy Embody
